Robert A Brodsky

List of Publications by Year
in descending order

272 papers	18,186 citations	17440 63 h-index	14208 128 g-index
274 all docs	274 docs citations	274 times ranked	15284 citing authors

#	Article	IF	Citations
1	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2008, 14, 641-650.	2.0	1,525
2	The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine, 2006, 355, 1233-1243.	27.0	1,060
3	Cyclophosphamide and cancer: golden anniversary. Nature Reviews Clinical Oncology, 2009, 6, 638-647.	27.6	675
4	Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnology, 2007, 25, 1256-1264.	17.5	657
5	Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood, 2008, 111, 1840-1847.	1.4	534
6	Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood, 2007, 110, 4123-4128.	1.4	481
7	Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Science Translational Medicine, 2014, 6, 265ra168.	12.4	440
8	Paroxysmal nocturnal hemoglobinuria. Blood, 2014, 124, 2804-2811.	1.4	424
9	Haploinsufficiency of t e lomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15960-15964.	7.1	423
10	HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood, 2012, 120, 4285-4291.	1.4	387
11	Butyrate Greatly Enhances Derivation of Human Induced Pluripotent Stem Cells by Promoting Epigenetic Remodeling and the Expression of Pluripotency-Associated Genes. Stem Cells, 2010, 28, 713-720.	3.2	385
12	High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood, 2010, 115, 3224-3230.	1.4	346
13	Longâ€term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 2013, 162, 62-73.	2.5	320
14	Whole-Genome Sequencing Analysis Reveals High Specificity of CRISPR/Cas9 and TALEN-Based Genome Editing in Human iPSCs. Cell Stem Cell, 2014, 15, 12-13.	11.1	315
15	Paroxysmal nocturnal haemoglobinuria. Nature Reviews Disease Primers, 2017, 3, 17028.	30.5	299
16	Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood, 2020, 136, 2080-2089.	1.4	283
17	Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biology of Blood and Marrow Transplantation, 2010, 16, 482-489.	2.0	260
18	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood, 2015, 125, 3024-3031.	1.4	259

#	Article	IF	Citations
19	Aplastic anaemia. Lancet, The, 2005, 365, 1647-1656.	13.7	251
20	Improved Detection and Characterization of Paroxysmal Nocturnal Hemoglobinuria Using Fluorescent Aerolysin. American Journal of Clinical Pathology, 2000, 114, 459-466.	0.7	246
21	Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. British Journal of Haematology, 2004, 126, 133-138.	2.5	218
22	Immunoablative High-Dose Cyclophosphamide without Stem-Cell Rescue for Refractory, Severe Autoimmune Disease. Annals of Internal Medicine, 1998, 129, 1031.	3.9	216
23	How I treat paroxysmal nocturnal hemoglobinuria. Blood, 2009, 113, 6522-6527.	1.4	216
24	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. Journal of Clinical Oncology, 2015, 33, 3152-3161.	1.6	215
25	Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica, 2014, 99, 922-929.	3.5	195
26	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood, 2014, 124, 3817-3827.	1.4	165
27	Diagnostic utility of telomere length testing in a hospital-based setting. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2358-E2365.	7.1	165
28	Long-Term Results of Blood and Marrow Transplantation for Hodgkinâ€™s Lymphoma. Journal of Clinical Oncology, 2001, 19, 4314-4321.	1.6	163
29	Severe COVIDâ€19 infection and thrombotic microangiopathy: success does not come easily. British Journal of Haematology, 2020, 189, e227-e230.	2.5	160
30	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica, 2017, 102, 391-400.	3.5	152
31	The Phenotype of a Germline Mutation in PIGA: The Gene Somatically Mutated in Paroxysmal Nocturnal Hemoglobinuria. American Journal of Human Genetics, 2012, 90, 295-300.	6.2	146
32	Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood, 2020, 135, 239-251.	1.4	145
33	Highâ€dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 48, 166-173.	6.7	136
34	Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplantation, 2008, 42, 523-527.	2.4	132
35	Treatment of refractory myasthenia: â€œRebootingâ€•with highâ€dose cyclophosphamide. Annals of Neurology, 2003, 53, 29-34.	5.3	127
36	Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative. Biology of Blood and Marrow Transplantation, 2019, 25, 1197-1209.	2.0	120

#	Article	IF	Citations
37	PIG-A mutations in normal hematopoiesis. Blood, 2005, 105, 3848-3854.	1.4	116
38	Partially Mismatched Transplantation and Human Leukocyte Antigen Donor-Specific Antibodies. Biology of Blood and Marrow Transplantation, 2013, 19, 647-652.	2.0	113
39	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematology,the, 2019, 6, e183-e193.	4.6	111
40	High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood, 2010, 115, 2136-2141.	1.4	107
41	Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Reviews, 2008, 22, 65-74.	5.7	105
42	High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood, 2002, 100, 704-706.	1.4	103
43	Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2013, 19, 1514-1517.	2.0	103
44	Narrative Review: Paroxysmal Nocturnal Hemoglobinuria: The Physiology of Complement-Related Hemolytic Anemia. Annals of Internal Medicine, 2008, 148, 587.	3.9	96
45	Durable Treatment-Free Remission after High-Dose Cyclophosphamide Therapy for Previously Untreated Severe Aplastic Anemia. Annals of Internal Medicine, 2001, 135, 477.	3.9	95
46	Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2017, 23, 498-504.	2.0	93
47	Resistance of Paroxysmal Nocturnal Hemoglobinuria Cells to the Glycosylphosphatidylinositol-Binding Toxin Aerolysin. Blood, 1999, 93, 1749-1756.	1.4	92
48	Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Advances, 2020, 4, 1770-1779.	5.2	92
49	Multilineage glycosylphosphatidylinositol anchorâ€deficient haematopoiesis in untreated aplastic anaemia. British Journal of Haematology, 2001, 115, 476-482.	2.5	88
50	Rebooting the Immune System with Highâ€Dose Cyclophosphamide for Treatment of Refractory Myasthenia Gravis. Annals of the New York Academy of Sciences, 2008, 1132, 305-314.	3.8	88
51	Modified Ham test for atypical hemolytic uremic syndrome. Blood, 2015, 125, 3637-3646.	1.4	88
52	Complement in the Pathophysiology of the Antiphospholipid Syndrome. Frontiers in Immunology, 2019, 10, 449.	4.8	87
53	Complementopathies. Blood Reviews, 2017, 31, 213-223.	5.7	86
54	Warm Autoimmune Hemolytic Anemia. New England Journal of Medicine, 2019, 381, 647-654.	27.0	86

#	Article	IF	Citations
55	Complement in hemolytic anemia. Blood, 2015, 126, 2459-2465.	1.4	84
56	Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Advances, 2017, 1, 288-292.	5.2	84
57	Direct evidence of complement activation in HELLP syndrome: A link toÂatypical hemolytic uremic syndrome. Experimental Hematology, 2016, 44, 390-398.	0.4	80
58	Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis. Archives of Neurology, 2008, 65, 1044-51.	4.5	78
59	Channels formed by subnanomolar concentrations of the toxin aerolysin trigger apoptosis of T lymphomas. Cellular Microbiology, 1999, 1, 69-74.	2.1	77
60	Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica, 2020, 106, 230-237.	3.5	77
61	Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica, 2017, 102, 466-475.	3.5	74
62	Eculizumab cessation in atypical hemolytic uremic syndrome. Blood, 2017, 130, 368-372.	1.4	70
63	Complementopathies and precision medicine. Journal of Clinical Investigation, 2020, 130, 2152-2163.	8.2	70
64	Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood, 2017, 129, 1389-1393.	1.4	69
65	Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia. European Journal of Haematology, 2011, 87, 37-45.	2.2	68
66	<scp>C3</scp> inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. American Journal of Hematology, 2020, 95, 1334-1343.	4.1	67
67	Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight, 2018, 3, .	5.0	65
68	Paroxysmal Nocturnal Hemoglobinuria from Bench to Bedside. Clinical and Translational Science, 2011, 4, 219-224.	3.1	64
69	How I treat paroxysmal nocturnal hemoglobinuria. Blood, 2021, 137, 1304-1309.	1.4	63
70	Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: Report of a case and review of this new therapy for severe autoimmune disease. Journal of the American Academy of Dermatology, 1999, 40, 750-754.	1.2	62
71	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Nonâ€“First-Degree Related Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1099-1102.	2.0	61
72	Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2018, 24, 343-352.	2.0	61

#	Article	IF	Citations
73	Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood, 2019, 134, 1037-1045.	1.4	58
74	Graft-versus-Host Reactions and the Effectiveness of Donor Lymphocyte Infusions. Biology of Blood and Marrow Transplantation, 2006, 12, 414-421.	2.0	56
75	Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes. European Journal of Haematology, 2014, 92, 467-470.	2.2	54
76	Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria. European Journal of Haematology, 2013, 90, 16-24.	2.2	52
77	Paroxysmal Nocturnal Hemoglobinuria. Hematology/Oncology Clinics of North America, 2015, 29, 479-494.	2.2	52
78	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Advances, 2020, 4, 3913-3925.	5.2	52
79	Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica, 2021, 106, 3188-3197.	3.5	52
80	Trophoblast Differentiation Defect in Human Embryonic Stem Cells Lacking PIG-A and GPI-Anchored Cell-Surface Proteins. Cell Stem Cell, 2008, 2, 345-355.	11.1	50
81	Clinical management of aplastic anemia. Expert Review of Hematology, 2011, 4, 221-230.	2.2	48
82	Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. Journal of Thrombosis and Haemostasis, 2021, 19, 607-616.	3.8	45
83	Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood, 2021, 138, 1928-1938.	1.4	45
84	Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. Journal of the American Academy of Dermatology, 2003, 49, 148-150.	1.2	44
85	High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. Experimental Hematology, 2004, 32, 435-440.	0.4	43
86	Highâ€dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: A prospective randomized trial. Arthritis and Rheumatism, 2010, 62, 1487-1493.	6.7	43
87	Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1887-1894.	2.0	42
88	Inhibited apoptosis and drug resistance in acute myeloid leukaemia. British Journal of Haematology, 1998, 102, 1042-1049.	2.5	41
89	Stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica, 2010, 95, 855-856.	3.5	40
90	Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, 2009, 84, 699-701.	4.1	39

#	Article	IF	Citations
91	High-dose cyclophosphamide for autoimmunity and alloimmunity. Immunologic Research, 2010, 47, 179-184.	2.9	39
92	Early Frameshift Mutation inPIGAIdentified in a Large XLID Family Without Neonatal Lethality. Human Mutation, 2014, 35, 350-355.	2.5	39
93	Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Leukemia Research, 2010, 34, 566-571.	0.8	38
94	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2019, 25, 1128-1135.	2.0	38
95	Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. British Journal of Haematology, 2020, 191, 476-485.	2.5	38
96	High-Dose Cyclophosphamide Without Stem Cell Rescue in 207 Patients With Aplastic Anemia and Other Autoimmune Diseases. Medicine (United States), 2011, 90, 89-98.	1.0	37
97	COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria. Blood, 2021, 137, 3670-3673.	1.4	37
98	PIG-A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesis. Leukemia and Lymphoma, 2006, 47, 1215-1221.	1.3	36
99	Differential Sensitivity to JAK Inhibitory Drugs by Isogenic Human Erythroblasts and Hematopoietic Progenitors Generated from Patient-Specific Induced Pluripotent Stem Cells. Stem Cells, 2014, 32, 269-278.	3.2	36
100	Blood and marrow transplantation for sickle cell disease: overcoming barriers to success. Current Opinion in Oncology, 2009, 21, 158-161.	2.4	35
101	Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Experimental Hematology, 2009, 37, 42-51.e1.	0.4	34
102	Complement dysregulation is associated with severe COVID-19 illness. Haematologica, 2022, 107, 1095-1105.	3.5	34
103	Pretransplant Genetic Susceptibility: Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy. Thrombosis and Haemostasis, 2020, 120, 638-646.	3.4	33
104	Paroxysmal Nocturnal Hemoglobinuria: Stem Cells and Clonality. Hematology American Society of Hematology Education Program, 2008, 2008, 111-115.	2.5	32
105	Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 2056-2064.	2.0	32
106	Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biology of Blood and Marrow Transplantation, 2003, 9, 312-319.	2.0	31
107	Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1022-1028.	2.0	29
108	Catheter-directed Thrombolysis and Thrombectomy for the Budd-Chiari Syndrome in Paroxysmal Nocturnal Hemoglobinuria in Three Patients. Journal of Vascular and Interventional Radiology, 2006, 17, 383-387.	0.5	27

#	Article	IF	Citations
109	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biology of Blood and Marrow Transplantation, 2015, 21, 2115-2122.	2.0	26
110	Bone marrow transplantation for autoimmune diseases. Current Opinion in Oncology, 1999, 11, 83.	2.4	25
111	The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2006, 108, 123-123.	1.4	25
112	High-dose cyclophosphamide for aplastic anemia and autoimmunity. Current Opinion in Oncology, 2002, 14, 143-146.	2.4	24
113	Induction of Autologous Graft-versus-Host Disease: Results of a Randomized Prospective Clinical Trial in Patients with Poor Risk Lymphoma. Biology of Blood and Marrow Transplantation, 2007, 13, 1185-1191.	2.0	24
114	Treatment of relapsingâ€“remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance. Multiple Sclerosis Journal, 2012, 18, 202-209.	3.0	24
115	Reduced sensitivity of <scp>PLASMIC</scp> and <scp>French</scp> scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals. Transfusion, 2021, 61, 266-273.	1.6	24
116	Oneâ€year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab. European Journal of Haematology, 2021, 106, 389-397.	2.2	24
117	Biology and management of acquired severe aplastic anemia. Current Opinion in Oncology, 1998, 10, 95-99.	2.4	22
118	Riddle: What do aplastic anemia, acute promyelocytic leukemia, and chronic myeloid leukemia have in common?. Leukemia, 2004, 18, 1740-1742.	7.2	22
119	Treatment of hepatitisâ€associated aplastic anemia with highâ€dose cyclophosphamide. Pediatric Blood and Cancer, 2007, 49, 947-951.	1.5	21
120	Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab. Liver Transplantation, 2009, 15, 540-543.	2.4	21
121	Purified GPI-Anchored CD4DAF as a Receptor for HIV-Mediated Gene Transfer. Human Gene Therapy, 1994, 5, 1231-1239.	2.7	20
122	High-dose therapy for autoimmune neurologic diseases. Current Opinion in Oncology, 2005, 17, 83-88.	2.4	20
123	Blood and marrow transplantation for sickle cell disease: Is less more?. Blood Reviews, 2014, 28, 243-248.	5.7	20
124	Typical Hus: Evidence of Acute Phase Complement Activation from a Daycare Outbreak. Journal of Clinical & Experimental Nephrology, 2016, 01, .	0.1	20
125	In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy. Blood Advances, 2017, 1, 1632-1634.	5.2	20
126	Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission. Blood Advances, 2022, 6, 1264-1270.	5.2	20

#	Article	IF	Citations
127	Silencing of genes required for glycosylphosphatidylinositol anchor biosynthesis in Burkitt lymphoma. Experimental Hematology, 2009, 37, 423-434.e2.	0.4	19
128	Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leukemia Research, 2011, 35, 87-94.	0.8	19
129	The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells. Haematologica, 2012, 97, 1225-1233.	3.5	19
130	Modification of the Eculizumab Dose to Successfully Manage Intravascular Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2008, 112, 3441-3441.	1.4	19
131	ELIMINATION OF ALLOANTIBODIES BY IMMUNOABLATIVE HIGH-DOSE CYCLOPHOSPHAMIDE 1. Transplantation, 2001, 71, 482-484.	1.0	18
132	New Insights into Paroxysmal Nocturnal Hemoglobinuria. Hematology American Society of Hematology Education Program, 2006, 2006, 24-28.	2.5	18
133	Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leukemia Research, 2008, 32, 1439-1447.	0.8	18
134	Generation of Glycosylphosphatidylinositol Anchor Protein-Deficient Blood Cells From Human Induced Pluripotent Stem Cells. Stem Cells Translational Medicine, 2013, 2, 819-829.	3.3	18
135	Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria. Experimental Hematology, 2014, 42, 857-861.e1.	0.4	18
136	Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia. Hematology/Oncology Clinics of North America, 2018, 32, 629-642.	2.2	18
137	HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatic Disease Clinics of North America, 2000, 26, 377-387.	1.9	17
138	Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience. British Journal of Haematology, 2002, 117, 907-913.	2.5	17
139	Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry. American Journal of Hematology, 2019, 94, E37-E41.	4.1	17
140	Sequential cellular niches control the generation of enucleated erythrocytes from human pluripotent stem cells. Haematologica, 2020, 105, e48-e51.	3.5	17
141	Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 2075-2081.	2.0	17
142	High Dose Cyclophosphamide Treatment for Autoimmune Disorders. Scientific World Journal, The, 2002, 2, 1808-1815.	2.1	16
143	Enhanced Cytotoxicity of Rituximab Following Genetic and Biochemical Disruption of Glycosylphosphatidylinositol Anchored Proteins. Leukemia and Lymphoma, 2004, 45, 795-800.	1.3	16
144	High-Dose Cyclophosphamide and Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus. JAMA - Journal of the American Medical Association, 2006, 295, 559.	7.4	16

#	Article	IF	Citations
145	Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment. Biology of Blood and Marrow Transplantation, 2018, 24, e26-e30.	2.0	16
146	Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia. Biology of Blood and Marrow Transplantation, 1999, 5, 394-399.	2.0	15
147	Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: Advantages and disadvantages. Autoimmunity, 2008, 41, 596-600.	2.6	15
148	How doPIG-Amutant paroxysmal nocturnal hemoglobinuria stem cells achieve clonal dominance?. Expert Review of Hematology, 2009, 2, 353-356.	2.2	15
149	The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2015, 13, 32-38.	1.9	15
150	Hypotonia and intellectual disability without dysmorphic features in a patient with PIGN-related disease. BMC Medical Genetics, 2017, 18, 124.	2.1	15
151	Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria. Hematology American Society of Hematology Education Program, 2018, 2018, 371-376.	2.5	15
152	Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 1903-1909.	2.0	14
153	Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation. Frontiers in Immunology, 2020, 11, 1460.	4.8	14
154	Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab. Hematology, 2020, 25, 327-334.	1.5	14
155	Eculizumab and aHUS: to stop or not. Blood, 2021, 137, 2419-2420.	1.4	14
156	Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Refractory Severe Aplastic Anemia (SAA). Blood, 2015, 126, 2031-2031.	1.4	14
157	Paroxysmal Nocturnal Hemoglobinuria Arising From Fanconi Anemia. Journal of Pediatric Hematology/Oncology, 2003, 25, 167-168.	0.6	13
158	Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leukemia and Lymphoma, 2013, 54, 483-490.	1.3	13
159	A caseâ€control analysis of hyperhemolysis syndrome in adults and laboratory correlates of complement involvement. Transfusion, 2019, 59, 3129-3139.	1.6	13
160	Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Advances, 2021, 5, 1504-1512.	5.2	13
161	A hypomorphic PIGA gene mutation causes severe defects in neuron development and susceptibility to complement-mediated toxicity in a human iPSC model. PLoS ONE, 2017, 12, e0174074.	2.5	13
162	Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases. American Journal of Blood Research, 2013, 3, 84-90.	0.6	13

#	Article	IF	Citations
163	Acquired sideroblastic anaemia following progesterone therapy. British Journal of Haematology, 1994, 87, 859-862.	2.5	12
164	A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy. Blood, 2019, 134, 3514-3514.	1.4	12
165	Haploidentical Bone Marrow Transplant with Post-Transplant Cytoxan Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Multicenter Learning Collaborative. Blood, 2016, 128, 1233-1233.	1.4	12
166	SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura. Blood, 2022, 139, 2570-2573.	1.4	12
167	High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. Journal of Pediatric Hematology/Oncology, 2016, 38, 627-635.	0.6	11
168	Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leukemia and Lymphoma, 2016, 57, 666-675.	1.3	11
169	Modified Ham Test Distinguishes aHUS from TTP and Predicts Response to Eculizumab. Blood, 2015, 126, 103-103.	1.4	11
170	High-dose cyclophosphamide in aplastic anaemia. Lancet, The, 2001, 357, 1128-1129.	13.7	10
171	â€œLetâ€•ing go with clonal expansion?. Blood, 2011, 117, 5788-5790.	1.4	10
172	Burst-forming unitâ€“erythroid assays to distinguish cellular bone marrow failure disorders. Experimental Hematology, 2013, 41, 808-816.	0.4	10
173	Definitive Hematopoietic Multipotent Progenitor Cells Are Transiently Generated From Hemogenic Endothelial Cells in Human Pluripotent Stem Cells. Journal of Cellular Physiology, 2016, 231, 1065-1076.	4.1	10
174	Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor. American Journal of Hematology, 2021, 96, E232-E235.	4.1	10
175	The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria. Therapeutic Advances in Hematology, 2022, 13, 204062072210910.	2.5	10
176	Isolated Clonal Cytogenetic Abnormalities after High-Dose Therapy. Biology of Blood and Marrow Transplantation, 2014, 20, 1130-1138.	2.0	9
177	Complement in hemolytic anemia. Hematology American Society of Hematology Education Program, 2015, 2015, 385-391.	2.5	9
178	High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e381.	6.0	9
179	PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. Oncotarget, 2017, 8, 29887-29905.	1.8	9
180	Major adverse cardiovascular events in survivors of immuneâ€•mediated thrombotic thrombocytopenic purpura. American Journal of Hematology, 2021, 96, 1587-1594.	4.1	9

#	Article	IF	Citations
181	The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-NaÃ¯ve and Refractory Severe Aplastic Anemia (SAA). Blood, 2019, 134, 147-147.	1.4	9
182	High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leukemia and Lymphoma, 2011, 52, 2076-2081.	1.3	8
183	Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition. Expert Review of Clinical Immunology, 2013, 9, 1113-1124.	3.0	8
184	Complement in Health and Disease. Hematology/Oncology Clinics of North America, 2015, 29, xi.	2.2	8
185	Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2020, 26, 2306-2310.	2.0	8
186	Are genetic approaches still needed to cure sickle cell disease?. Journal of Clinical Investigation, 2019, 130, 7-9.	8.2	8
187	GPI-Anchored Protein Deficiency Confers Resistance to Apoptosis in PNH.. Blood, 2008, 112, 2035-2035.	1.4	8
188	Eculizumab: another breakthrough. Blood, 2017, 129, 922-923.	1.4	7
189	Defining early hematopoieticâ€fated primitive streak specification of human pluripotent stem cells by the orchestrated balance of Wnt, activin, and BMP signaling. Journal of Cellular Physiology, 2019, 234, 16136-16147.	4.1	7
190	Ex vivo assays to detect complement activation in complementopathies. Clinical Immunology, 2020, 221, 108616.	3.2	7
191	Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies. Blood, 2018, 132, 626-626.	1.4	7
192	Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies. Blood, 2019, 134, 952-952.	1.4	7
193	Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria?. British Journal of Haematology, 2022, 196, 264-265.	2.5	7
194	A Rapid Spectrophotometric Screening Assay for Paroxysmal Nocturnal Hemoglobinuria. Acta Haematologica, 2002, 107, 182-184.	1.4	6
195	Parvovirus b19-associated pure red cell aplasia in chronic graft-versus-host disease. British Journal of Haematology, 2002, 119, 280-281.	2.5	6
196	A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway. Journal of Maternal-Fetal and Neonatal Medicine, 2020, , 1-9.	1.5	6
197	Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency. Journal of Clinical Investigation, 2019, 129, 5074-5076.	8.2	6
198	Post-Transplantation Cyclophosphamide (Cy) Reduces Graft Rejection and Graft-Versus-Host Disease (GVHD) after Non-Myeloablative, Partially HLA-Mismatched (Haploidentical) Bone Marrow Transplantation (BMT).. Blood, 2004, 104, 437-437.	1.4	6

#	Article	IF	Citations
199	Post-Transplantation High Dose Cyclophosphamide (Cy) Is Effective Single Agent for Prevention of Acute and Chronic Graft Versus Host Disease after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT). Blood, 2008, 112, 56-56.	1.4	6
200	Use of Blood Transfusions In Paroxysmal Nocturnal Hemoglobinuria Patients with and without Aplastic Anemia Enrolled In the Global PNH Registry. Blood, 2010, 116, 2241-2241.	1.4	6
201	Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic. Blood, 2019, 134, 4-4.	1.4	6
202	A 15â€year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism. American Journal of Hematology, 2022, 97, .	4.1	6
203	Pegcetacoplan for paroxysmal nocturnal hemoglobinuria. Blood, 2022, 139, 3361-3365.	1.4	6
204	Pentostatin-induced hypereosinophilia with eosinophilic gastroenteritis. Leukemia and Lymphoma, 2010, 51, 1567-1569.	1.3	5
205	Idiopathic Inflammatory Myopathy Treated With High-Dose Immunoablative Cyclophosphamideâ€”A Long-term Follow-up Study. JAMA Neurology, 2015, 72, 1205.	9.0	5
206	Single-board hematology fellowship track: a 10-year institutional experience. Blood, 2018, 131, 462-464.	1.4	5
207	A complementary new drug for PNH. Blood, 2020, 135, 884-885.	1.4	5
208	One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment. Blood, 2019, 134, 2231-2231.	1.4	5
209	Evaluation of Paroxysmal Nocturnal Hemoglobinuria Disease Burden: The Patient's Perspective. A Report From the International PNH Registry.. Blood, 2010, 116, 1525-1525.	1.4	5
210	Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease: BMT CTN Protocol 1507. Blood, 2019, 134, 802-802.	1.4	5
211	Treatment versus Transplant for Challenging Hematologic Disorders. Biology of Blood and Marrow Transplantation, 2009, 15, 72-78.	2.0	4
212	High-Dose Cyclophosphamide Without Stem Cell Rescue for the Treatment of Refractory Behcet's Disease. Seminars in Arthritis and Rheumatism, 2011, 41, 301-304.	3.4	4
213	Balancing Therapy with Thrombopoietin Receptor Agonists and Splenectomy in Refractory Immune Thrombocytopenic Purpura: A Case of Postsplenectomy Thrombocytosis Requiring Plateletpheresis. Case Reports in Hematology, 2016, 2016, 1-4.	0.4	4
214	Pain Experiences of Adults With Sickle Cell Disease and Hematopoietic Stem Cell Transplantation: A Qualitative Study. Pain Medicine, 2021, 22, 1753-1759.	1.9	4
215	A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2018, 132, 2330-2330.	1.4	4
216	Effect of the Terminal Complement Inhibitor Eculizumab on Patient Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase III Triumph Study Results.. Blood, 2006, 108, 3770-3770.	1.4	4

#	Article	IF	Citations
217	Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2010, 116, 4237-4237.	1.4	4
218	Small Molecule Factor D Inhibitors Block Complement Activation in Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome. Blood, 2015, 126, 275-275.	1.4	4
219	High-dose cyclophosphamide in severe aplastic anaemia. British Journal of Haematology, 2004, 125, 408-409.	2.5	3
220	Acquired severe aplastic anemia in children: Is there a standard of care?. Pediatric Blood and Cancer, 2004, 43, 711-712.	1.5	3
221	Acquired severe aplastic anemia in children: Is there a standard of care?. Pediatric Blood and Cancer, 2005, 45, 361-362.	1.5	3
222	Severe aplastic anemia associated with paroxysmal nocturnal hemoglobinuria and lymphoplasmacytic lymphoma. Leukemia and Lymphoma, 2005, 46, 1243-1246.	1.3	3
223	Bronchobiliary Fistula and Lithoptysis after Endoscopic Retrograde Cholangiopancreatography and Liver Biopsy in a Patient with Paroxysmal Nocturnal Hemoglobinuria. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 451-454.	5.6	3
224	Genetic panels in young patients with bone marrow failure: are they clinically relevant?. Haematologica, 2016, 101, 1275-1276.	3.5	3
225	PIGN spatiotemporally regulates the spindle assembly checkpoint proteins in leukemia transformation and progression. Scientific Reports, 2021, 11, 19022.	3.3	3
226	Phase 3 Study of Danicopan, an Oral Complement Factor D Inhibitor, As Add-on Therapy to a C5 Inhibitor in Patients with Paroxysmal Nocturnal Hemoglobinuria with Clinically Evident Extravascular Hemolysis. Blood, 2020, 136, 6-7.	1.4	3
227	High Dose Cyclophosphamide (CY) for Severe Aplastic Anemia (SAA): Safety and Long Term Follow-Up.. Blood, 2005, 106, 129-129.	1.4	3
228	Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2007, 110, 3672-3672.	1.4	3
229	Updates in the Management of Warm Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America, 2022, 36, 325-339.	2.2	3
230	Acquired Aplastic Anemia. , 2014, , 685-694.		2
231	Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2019, 134, 2226-2226.	1.4	2
232	Clinical Characteristics of Classic Paroxysmal Nocturnal Hemoglobinuria (PNH) in Pediatric Patients: A Comparison with Classic PNH in Adults. An International PNH Registry Study. Blood, 2011, 118, 2102-2102.	1.4	2
233	Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy). Blood, 2013, 122, 3407-3407.	1.4	2
234	Evaluation of Bacteria-Mediated Potential "Bystander" Hemolysis of PNH RED CELLS In Vitro: NO Evidence of Significant Complement Classical or Lectin Pathway-Mediated Hemolysis Induced by Microorganisms. Blood, 2016, 128, 2431-2431.	1.4	2

#	Article	IF	Citations
235	Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2). Blood, 2020, 136, 8-9.	1.4	2
236	Paroxysmal Nocturnal Hemoglobinuria. , 2018, , 415-424.		1
237	An Alternative Pathway Specific Flow Cytometric Assay to Detect Complement Activation in Atypical Hemolytic Uremic Syndrome (aHUS). Blood, 2018, 132, 3748-3748.	1.4	1
238	Chronic Kidney Disease, Hypertension and Cardiovascular Sequelae during Long Term Follow up of Adults with Atypical Hemolytic Uremic Syndrome. Blood, 2018, 132, 3754-3754.	1.4	1
239	Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2012, 120, 1260-1260.	1.4	1
240	A Germline Mutation in ERBB3 Predisposes to Inherited Erythroid Myelodysplasia/Erythroleukemia. Blood, 2015, 126, 4105-4105.	1.4	1
241	The origin of GPI-AP deficient cells in MDS, MPD, and aplastic anemia and its significance in predicting leukemic transformation.. Journal of Clinical Oncology, 2013, 31, 7032-7032.	1.6	1
242	Predictors of Response to Eculizumab Therapy in Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2012, 120, 2357-2357.	1.4	1
243	Abundance of B Cell Receptors Harboring Elongated Polytyrosine and Polyserine Rich Motifs within Their Heavy Chain CDR3 Distinguishes Catastrophic and Antiphospholipid Syndrome. Blood, 2021, 138, 2117-2117.	1.4	1
244	Silent Cerebral Infarction on Brain MRI Is Associated with Cognitive Impairment in Ittp Survivors in Hematological Remission. Blood, 2021, 138, 774-774.	1.4	1
245	High-dose cyclophosphamide used to treat aplastic anemia in a patient with respiratory and food allergies has a prolonged effect on serum IgE levels. Journal of Allergy and Clinical Immunology, 2013, 132, 237-239.	2.9	0
246	The Use of Post-Transplantation Cyclophosphamide after Myeloablative, HLA-Matched Allogeneic Bone Marrow Transplantation Minimizes the Need for Additional Immunosuppression. Biology of Blood and Marrow Transplantation, 2016, 22, S46-S47.	2.0	0
247	Epidemiology in PNH: The PNH Global Registry. , 2017, , 99-107.		0
248	Paroxysmal Nocturnal Hemoglobinuria. , 0, , 137-142.		0
249	Properdin is a key player in lysis of red blood cells in aHUS and PNH. Molecular Immunology, 2018, 102, 139-140.	2.2	0
250	Complement-Mediated Coagulation Disorders. , 2019, , 473-490.		0
251	Acquired Aplastic Anemia. , 2020, , 923-934.		0
252	Factor B inhibition for paroxysmal nocturnal haemoglobinuria. Lancet Haematology,the, 2021, 8, e309-e310.	4.6	0

#	Article	IF	Citations
253	PIG-A Mutations in Normal Hematopoiesis.. Blood, 2004, 104, 2825-2825.	1.4	0
254	Treatment of Hepatitis-Associated Aplastic Anemia with High Dose Cyclophosphamide.. Blood, 2006, 108, 975-975.	1.4	0
255	Developmental Potentials of Human Embryonic Stem Cells Lacking PIG-A and GPI-Anchored Proteins.. Blood, 2006, 108, 1314-1314.	1.4	0
256	Silencing of Genes Required for Glycosylphosphatidylinositol Biosynthesis in a Burkittsâ€™ Lymphoma Cell Line (Ramos) and Hematopoietic Stem Cells (HSC).. Blood, 2006, 108, 1191-1191.	1.4	0
257	Anti-Leukemic Activity of Mitochondrially-Directed Asymmetrical 2-2'-Binaphthoquinones.. Blood, 2009, 114, 4799-4799.	1.4	0
258	Efficacy of a Brief, Cyclophosphamide-Intensive Regimen for Older Patients with Newly Diagnosed Burkitt's or Atypical Burkitt's Lymphoma/Leukemia.. Blood, 2009, 114, 2685-2685.	1.4	0
259	A Global Registry of Patients with Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2009, 114, 3007-3007.	1.4	0
260	High Dose Cyclophosphamide (HD CY) without Hematopoietic Stem Cell Transplantation (HSCT) in Refractory Severe Autoimmune Diseases: 11 Year Experience in Over 100 Patients.. Blood, 2009, 114, 3412-3412.	1.4	0
261	Natural History of Paroxysmal Nocturnal Hemoglobinuria Clones In Patients Presenting as Aplastic Anemia. Blood, 2010, 116, 4428-4428.	1.4	0
262	Relevance of Minor PIG-A Mutations In Acquired Aplastic Anemia and Myelodysplastic Syndromes. Blood, 2010, 116, 4433-4433.	1.4	0
263	Burst-Forming Unit-Erythroid Assays (BFU-E) Can Help Distinguish Cellular Bone Marrow Failure Disorders. Blood, 2012, 120, 3475-3475.	1.4	0
264	Eculizumab Protects Against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study. Blood, 2012, 120, 3480-3480.	1.4	0
265	Generation of GPI Anchor Deficient Blood Cells From Human iPSCs.. Blood, 2012, 120, 2358-2358.	1.4	0
266	The effect of therapeutic anticoagulation on overall survival (OS) in men receiving docetaxel chemotherapy for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2013, 31, 28-28.	1.6	0
267	Direct Evidence of Complement Activation in HELLP Syndrome: A Link to Atypical Hemolytic Uremic Syndrome. Blood, 2015, 126, 1047-1047.	1.4	0
268	Complement in hemolytic anemia. Hematology American Society of Hematology Education Program, 2015, 2015, 385-391.	2.5	0
269	Second Blood or Marrow Transplant (BMT) for Relapse: Mismatch Haplotype Switch May Improve Outcome. Blood, 2016, 128, 2252-2252.	1.4	0
270	Î²-2-Glycoprotein Antibodies Activate the Alternative Pathway of Complement in Antiphospholipid Antibody Syndrome. Blood, 2016, 128, 3818-3818.	1.4	0

#	Article	IF	Citations
271	PIG-a Gene Expression Deficiency Association with Reduced DNA Damage Checkpoint Response and Activation. Blood, 2018, 132, 3875-3875.	1.4	0
272	Prevalence and Characteristics of Venous Thromboembolism in Patients with Complement Mediated Thrombotic Microangiopathy. Blood, 2021, 138, 2091-2091.	1.4	0